John K Chan1, Chunqiao Tian, Deanna Teoh, Bradley J Monk, Thomas Herzog, Daniel S Kapp, Jeffrey Bell. 1. Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, Division of Gynecologic Oncology, San Francisco School of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143-1702, USA. chanjohn@obgyn.ucsf.edu
Abstract
OBJECTIVE: This study aimed to evaluate the clinical outcome of recurrent early-stage high-risk epithelial ovarian cancer patients. METHODS: Demographic and clinicopathological data were collected from women enrolled in GOG 157 who underwent surgical staging and had recurrent disease. Survival probability was estimated using Kaplan-Meier method, and hazard ratio of death was analyzed using Cox regression model. RESULTS: Of 74 women with recurrent early-stage high-risk ovarian cancer, the median age at recurrence was 63 years; 93% were White, 2.7% were Black, 2.7% were Asian, and 1.4% were Others. Fifty-eight percent had stage I, and the remainder had stage II disease. Clear cell, serous, endometrioid, mucinous, and other tumors consisted of 28.4%, 25.7%, 24.3%, 16.2%, and 5.4% of patients, respectively; in addition, 36.5% had ascites, 33.8% had positive cytology, and 43.2% had ruptured tumors. Fifty-eight percent underwent three cycles, and 42% had six cycles of adjuvant chemotherapy with paclitaxel and carboplatin. Recurrence was diagnosed clinically in 46% and radiographically in 54% of women. The median time from completion of primary chemotherapy to recurrence (treatment-free interval, TFI) was 21 months. Overall, median survival after recurrence was 24 months. Patients with longer (>24 months) TFI had a higher median survival after subsequent treatment at 35 months compared to only 10 months in those who recurred <or=24 months (p=0.003). CONCLUSIONS: Although patients with primary early-stage high-risk ovarian cancer have an overall favorable prognosis, survival after recurrence is poor and comparable to those with recurrent advanced-stage disease. Novel therapeutic modalities are warranted in these high-risk patients.
RCT Entities:
OBJECTIVE: This study aimed to evaluate the clinical outcome of recurrent early-stage high-risk epithelial ovarian cancerpatients. METHODS: Demographic and clinicopathological data were collected from women enrolled in GOG 157 who underwent surgical staging and had recurrent disease. Survival probability was estimated using Kaplan-Meier method, and hazard ratio of death was analyzed using Cox regression model. RESULTS: Of 74 women with recurrent early-stage high-risk ovarian cancer, the median age at recurrence was 63 years; 93% were White, 2.7% were Black, 2.7% were Asian, and 1.4% were Others. Fifty-eight percent had stage I, and the remainder had stage II disease. Clear cell, serous, endometrioid, mucinous, and other tumors consisted of 28.4%, 25.7%, 24.3%, 16.2%, and 5.4% of patients, respectively; in addition, 36.5% had ascites, 33.8% had positive cytology, and 43.2% had ruptured tumors. Fifty-eight percent underwent three cycles, and 42% had six cycles of adjuvant chemotherapy with paclitaxel and carboplatin. Recurrence was diagnosed clinically in 46% and radiographically in 54% of women. The median time from completion of primary chemotherapy to recurrence (treatment-free interval, TFI) was 21 months. Overall, median survival after recurrence was 24 months. Patients with longer (>24 months) TFI had a higher median survival after subsequent treatment at 35 months compared to only 10 months in those who recurred <or=24 months (p=0.003). CONCLUSIONS: Although patients with primary early-stage high-risk ovarian cancer have an overall favorable prognosis, survival after recurrence is poor and comparable to those with recurrent advanced-stage disease. Novel therapeutic modalities are warranted in these high-risk patients.
Authors: Peter G Rose; James J Java; Ritu Salani; Melissa A Geller; Angeles Alvarez Secord; Krishnansu S Tewari; David P Bender; David G Mutch; Michael L Friedlander; Linda Van Le; Michael W Method; Chad A Hamilton; Roger B Lee; Robert M Wenham; Saketh R Guntupalli; Maurie Markman; Franco M Muggia; Deborah K Armstrong; Michael A Bookman; Robert A Burger; Larry J Copeland Journal: Obstet Gynecol Date: 2019-02 Impact factor: 7.661
Authors: Helen E Dinkelspiel; Ana I Tergas; Lilli A Zimmerman; William M Burke; June Y Hou; Ling Chen; Grace Hillyer; Alfred I Neugut; Dawn L Hershman; Jason D Wright Journal: Gynecol Oncol Date: 2015-02-20 Impact factor: 5.482
Authors: John K Chan; Chunqiao Tian; Joshua P Kesterson; Bradley J Monk; Daniel S Kapp; Brittany Davidson; Sharon Robertson; Larry J Copeland; Joan L Walker; Robert M Wenham; Yovanni Casablanca; Nick M Spirtos; Krishnansu S Tewari; Jeffrey G Bell Journal: Obstet Gynecol Date: 2022-02-01 Impact factor: 7.623
Authors: Kelsey L Corrigan; Alison Yoder; Brian De; Lilie Lin; Anuja Jhingran; Melissa M Joyner; Patricia J Eifel; Lauren E Colbert; Karen H Lu; Ann H Klopp Journal: Gynecol Oncol Date: 2021-12-30 Impact factor: 5.304
Authors: David Cibula; Lukáš Dostálek; Jiri Jarkovsky; Constantijne H Mom; Aldo Lopez; Henrik Falconer; Giovanni Scambia; Ali Ayhan; Sarah H Kim; David Isla Ortiz; Jaroslav Klat; Andreas Obermair; Giampaolo Di Martino; Rene Pareja; Ranjit Manchanda; Jan Kosťun; Ricardo Dos Reis; Mehmet Mutlu Meydanli; Diego Odetto; Rene Laky; Ignacio Zapardiel; Vit Weinberger; Klára Benešová; Martina Borčinová; Fernando Cardenas; Emelie Wallin; Luigi Pedone Anchora; Huseyin Akilli; Nadeem R Abu-Rustum; Salim Abraham Barquet-Muñoz; Veronika Javůrková; Daniela Fischerová; Luc R C W van Lonkhuijzen Journal: Gynecol Oncol Date: 2021-12-23 Impact factor: 5.304
Authors: Tao Dao; Martin G Klatt; Tatyana Korontsvit; Sung Soo Mun; Sean Guzman; Marissa Mattar; Oliver Zivanovic; Chrisann K Kyi; Nicholas D Socci; Roisin E O'Cearbhaill; David A Scheinberg Journal: Cancer Immunol Immunother Date: 2020-10-29 Impact factor: 6.968
Authors: Ingiridur Skirnisdottir; Markus Mayrhofer; Maria Rydåker; Helena Akerud; Anders Isaksson Journal: BMC Cancer Date: 2012-09-12 Impact factor: 4.430